Select Transactions

Acquisition of
$225 million
September 2020
Rubicon Research
Majority recap by
General Atlantic Partners
$125 million
April 2019
Avenue Therapeutics
Sale of stock and conditional sale to
$215 million + CVRs
February 2019
Acquisition of
generics business of
$1.05 billion
June 2017
Torreya is a leading strategic M&A advisor to global life sciences companies.   MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales.   MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations.   MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals.   MORE

The Pharma 1000
Top Global Pharmaceutical Company Report

September 2020

Torreya report provides a snapshot of the global pharmaceutical industry in September 2020 and compares it to the industry in 2015.

Click Here for Report Executive Summary   |   Full Report (PDF 38.3MB)   |   Slide Overview (PDF 6.2MB)